Literature DB >> 28915348

Activation of factor XIII is accompanied by a change in oligomerization state.

Boris A Anokhin1, Vilius Stribinskis2, William L Dean2,3,4, Muriel C Maurer1.   

Abstract

Factor XIII A (FXIIIA) is a member of the transglutaminase enzyme family that cross-links both intra- and extracellular protein substrates. To prevent undesired cross-linking, FXIIIA is expressed as an inactive zymogen and exists intracellularly as an A2 homodimer. In plasma, FXIII A2 is complexed with two protective factor XIII B subunits (A2 B2 ) that dissociate upon activation of the zymogen. Based on limited experimental data, activated FXIII was considered a dimer of two catalytically active A subunits. However, accumulating but indirect evidence has suggested activation may lead to a monomeric state instead. In the present study, we employed analytical ultracentrifugation (AUC) to directly explore the oligomerization state of zymogen as well as active FXIIIA in solution. We first confirmed that the zymogen was a FXIIIA2 dimer. When we activated FXIIIA nonproteolytically (by high mm Ca2+ ), the protein dissociated to monomers. More importantly, FXIIIA incubation with its physiological partner, the protease thrombin, led to a monomeric state as well. AUC studies of partially cleaved FXIIIA further suggested that thrombin cleavage of a single activation peptide in a zymogen dimer is sufficient to weaken intersubunit interactions, initiating the transition to monomer. The enzymatic activity of the thrombin-cleaved species was higher than nonproteolytically activated enzyme, suggesting that displacement of the activation peptide renders the FXIIIA more accessible to substrates. Thus, results provide evidence that FXIII undergoes a change in oligomerization state as part of the activation process, and emphasize the role of the activation peptide in preventing FXIIIA catalytic activity. ENZYMES: Factor XIIIA (EC2.3.2.13).
© 2017 Federation of European Biochemical Societies.

Entities:  

Keywords:  analytical ultracentrifugation; factor XIII; oligomerization state; size exclusion chromatography; transglutaminase

Mesh:

Substances:

Year:  2017        PMID: 28915348      PMCID: PMC6075653          DOI: 10.1111/febs.14272

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  39 in total

1.  A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma.

Authors:  L Kárpáti; B Penke; E Katona; I Balogh; G Vámosi; L Muszbek
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327

2.  Coagulation factor XIIIa is inactivated by plasmin.

Authors:  Woosuk S Hur; Nima Mazinani; X J David Lu; Heidi M Britton; James R Byrnes; Alisa S Wolberg; Christian J Kastrup
Journal:  Blood       Date:  2015-09-10       Impact factor: 22.113

3.  A photometric assay for blood coagulation factor XIII.

Authors:  K Fickenscher; A Aab; W Stüber
Journal:  Thromb Haemost       Date:  1991-05-06       Impact factor: 5.249

4.  Impaired dimer assembly and decreased stability of naturally recurring R260C mutant A subunit for coagulation factor XIII.

Authors:  Shoko Maeda; Wei Guang Zhang; Masayoshi Souri; Vivien C Yee; Akitada Ichinose
Journal:  J Biochem       Date:  2012-08-25       Impact factor: 3.387

5.  Enzyme-linked immunosorbent assay for the determination of blood coagulation factor XIII A-subunit in plasma and in cell lysates.

Authors:  E Katona E; E Ajzner; K Tóth; L Kárpáti; L Muszbek
Journal:  J Immunol Methods       Date:  2001-12-01       Impact factor: 2.303

6.  Platelet factor XIII becomes active without the release of activation peptide during platelet activation.

Authors:  L Muszbek; J Polgár; Z Boda
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

7.  Normal range of mean platelet volume in healthy subjects: Insight from a large epidemiologic study.

Authors:  Hilmi Demirin; Hakan Ozhan; Taner Ucgun; Ahmet Celer; Sule Bulur; Habip Cil; Cemalettin Gunes; Hayriye Ak Yildirim
Journal:  Thromb Res       Date:  2011-05-28       Impact factor: 3.944

8.  Expression, purification, and characterization of human factor XIII in Saccharomyces cerevisiae.

Authors:  P D Bishop; D C Teller; R A Smith; G W Lasser; T Gilbert; R L Seale
Journal:  Biochemistry       Date:  1990-02-20       Impact factor: 3.162

9.  Mapping of factor XIII solvent accessibility as a function of activation state using chemical modification methods.

Authors:  Brian T Turner; T Michael Sabo; Diana Wilding; Muriel C Maurer
Journal:  Biochemistry       Date:  2004-08-03       Impact factor: 3.162

10.  Non-proteolytic activation of cellular protransglutaminase (placenta macrophage factor XIII).

Authors:  J Polgár; V Hidasi; L Muszbek
Journal:  Biochem J       Date:  1990-04-15       Impact factor: 3.857

View more
  7 in total

1.  Factor XIII topology: organization of B subunits and changes with activation studied with single-molecule atomic force microscopy.

Authors:  Anna D Protopopova; Andrea Ramirez; Dmitry V Klinov; Rustem I Litvinov; John W Weisel
Journal:  J Thromb Haemost       Date:  2019-03-14       Impact factor: 5.824

2.  Proteolytic and nonproteolytic activation mechanisms result in conformationally and functionally different forms of coagulation factor XIII A.

Authors:  Boris A Anokhin; William L Dean; Kerrie A Smith; Matthew J Flick; Robert A S Ariëns; Helen Philippou; Muriel C Maurer
Journal:  FEBS J       Date:  2019-08-28       Impact factor: 5.542

Review 3.  Fibrinogen and Factor XIII in Venous Thrombosis and Thrombus Stability.

Authors:  Alisa S Wolberg; Yaqiu Sang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-06-02       Impact factor: 10.514

4.  The Structure of Blood Coagulation Factor XIII Is Adapted to Oxidation.

Authors:  Alexandra Vasilyeva; Lyubov Yurina; Alexander Shchegolikhin; Maria Indeykina; Anna Bugrova; Alexey Kononikhin; Eugene Nikolaev; Mark Rosenfeld
Journal:  Biomolecules       Date:  2020-06-17

5.  Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a).

Authors:  Ralf Pasternack; Christian Büchold; Robert Jähnig; Christiane Pelzer; Michael Sommer; Andreas Heil; Peter Florian; Götz Nowak; Uwe Gerlach; Martin Hils
Journal:  J Thromb Haemost       Date:  2019-10-23       Impact factor: 5.824

6.  The Plasma Factor XIII Heterotetrameric Complex Structure: Unexpected Unequal Pairing within a Symmetric Complex.

Authors:  Sneha Singh; Alexis Nazabal; Senthilvelrajan Kaniyappan; Jean-Luc Pellequer; Alisa S Wolberg; Diana Imhof; Johannes Oldenburg; Arijit Biswas
Journal:  Biomolecules       Date:  2019-11-21

7.  Structure functional insights into calcium binding during the activation of coagulation factor XIII A.

Authors:  Sneha Singh; Johannes Dodt; Peter Volkers; Emma Hethershaw; Helen Philippou; Vytautus Ivaskevicius; Diana Imhof; Johannes Oldenburg; Arijit Biswas
Journal:  Sci Rep       Date:  2019-08-05       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.